\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesEIT Health's Flagship Calls 2025 invite the EIT Health communities, and beyond, to work on tackling specific challenges relating to health priority areas.
Currently, the Flagship call on 'Digital Tranformation of Healthcare' is open with deadline on 5 November 2024. This Flagship aims to support the digital health transformation in Europe and has two focus points: the development of, and access to, digital health medical devices, and the implementation of the European Health Data Space by exploring the secondary use of data. It will also look at how to train and develop patients, citizens, and healthcare professionals on the importance of using and sharing data and digital tools to enhance the quality-of-care pathways.
Who could apply? If you’re part of the healthcare industry, a start-up, a public health body, a policymaker, an academic institution, or corporate focused on business, education, research, or health service delivery, the EIT Health Flagship Call 2025 is designed for you. This is not an exhaustive list.
Missed EIT Health's informational webinar for applicants? Catch up with the webinar recording and presentation slides.
More information on the call and on how to apply on the EIT Health website (scroll down for this particular flagship).
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
